Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Flotetuzumab for primary refractory and early relapsed AML

John DiPersio • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Antibodies Flotetuzumab

John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, presents additional scientific data supporting the investigation of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in salvage therapy for primary refractory and early relapsed acute myeloid leukemia patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from John DiPersio

4:02
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio • 21 Feb 2023
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
4:19
Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients
John DiPersio • 21 Feb 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals